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From the Editor’s Desk
In the last decade, there has been a rapid expansion
of healthcare services in Pakistan. Correspondingly,
the consumer knowledge has also increased and they
demand quality services in timely manner. Clinical
laboratory is the center point of these services as over
70 per cent decisions are taken based on laboratory
results.
The most important component throughout this
whole process is quality assurance. With increasing
awareness amongst patients along with increasing
costs, a significant onus and urgency is placed on
clinical laboratories to ensure that quality and error
free work practices are maintained.
Over the years, the improvement in the quality of
tests and methodology has been steady. Following
the introduction of laboratory automation, quality
assurance has been taken to a new level. Instruments
have been interfaced with various laboratory
automated systems and subsequently, information
technology has drastically reduced human

intervention during analytical procedure without
compromising on the level of care.
Errors and challenges continue to occur but time has
indicated that the path to improvement is not always
a straight line; there are periods of success and
periods of massive failures. Laboratory improvement
has been a steadfast experience till now. One lesson
to be learnt from this experience is that we cannot
predict all errors; but through active quality process
we can detect errors earlier and prevent them from
happening.
This issue has been focused on articles pertaining to
quality assurance in a clinical laboratory. The articles
have been carefully selected so that our readers
can build upon the culture of quality assurance and
increase knowledge of the same by following the
goal of continuous improvement.
Dr Natasha Ali
Haematology

An Overview of Proficiency Testing
Dr Hafsa Majid
Chemical Pathology

An important aspect of clinical laboratory quality
management is ‘Quality Assessment’, and it can
be conducted in several ways. Internal quality
control compares laboratory performance to
itself over time, assuming that the performance
observed earlier represents correct or accurate
test results. This assumption should be validated
initially by method validation experiments and
must be validated on a continuing basis by
external quality assessment (EQA) or proficiency
testing (PT) programs. It is also mandated by
accreditation bodies that laboratories participate in
PT programs for all types of analyses undertaken
in that laboratory. In cases where PT programs are
not available for a specific analytes alternate PT
methods (split sample testing, sending specimen to
reference laboratory for analysis) should be adopted
for EQA.

The EQA or PT programs refer to the process of
controlling the accuracy of an analytical method
by interlaboratory comparisons. This comparison
can be made to the performance of a peer
group of laboratories or to the performance of a
reference laboratory. The key requirements of such
comparisons are that the samples are homogenous
and stable, matrix is as similar as possible to patient
specimen and the instrument, method, calculations
and units used are appropriate and similar to
comparing laboratories.
Benefits of PT Programmes
Proficiency testing is used to judge the quality of
laboratory testing.The unique capability of an EQA
program is to monitor the accuracy of methods/
instruments and make sure that the performance
3
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of a laboratory’s method is stable on the period
between two surveys. Harmonization of results
among laboratories and among methods is another
important objective of EQA because clinical practice
guidelines can be standardized if results are consistent
among different laboratories. By participating in
PT programs, a laboratory can maintain a level of
competence comparable with other laboratories.
Continued and significant deviation in PT should alert
a clinical laboratory to a possible accuracy problem.
PT Providers
Multiple private organizations are providing PT surveys
of different analytes. Common ones include College of
American Pathologist, American Proficiency Institute,
United Kingdom National External Quality Assessment
Service, Centers for Disease Control and Prevention,
BIO-Rad External Quality Assessment Services and
National External Quality Assurance Program Pakistan.
Two types of surveys are available; peer group
comparison and accuracy based survey. In accuracy
based survey actual value of PT sample measured
by a reference method and individual laboratory’s
results are compared with true or target value of PT
specimen. Proficiency testing provider is selected on
basis of national and regulatory agencies requirement,
previous surveys of that PT provider, surveys taken
by other regional laboratories, cost of surveys, type
of comparison and commutability of PT specimen.
Frequency of PT testing is recommended by different
regulatory authorities, at least twice a year and more
frequent for routine analytes.
PT Report Interpretation
Peer group comparison is the common method used
by PT providers, same PT specimen is sent to all

laboratories participating in a survey and results
are reported as mean, standard deviation (SD),
standard deviation index (SDI), control limits for
each analytes and graph of previous and current
survey. A peer group is comprised of at least 10 or
more laboratories performing same analyte on same
instrument using same method and reporting in
similar units. If no peer group is formed laboratory
is evaluated against all methods mean. Limits for
all analytes is different based regulatory authority’s
acceptability criteria and biological variation. A
laboratory’s results are acceptable if within limits.
Standard deviation index (SDI) is another accuracy
measure calculated by (Laboratory’s mean – Peer
group mean)/ Peer group SD and it should be
<2. Acceptable PT results with high SDI should
alert laboratory to system’s bias. Last to look at
in a PT survey is graph for bias. Ideally a graph
should show PT results near and on both sides
of mean. Graph showing results of previous and
current surveys on one side of mean shows positive
or negative bias in a system. For a survey to be
acceptable at least 80% of PT results should be
acceptable.
Proficiency testing results can be affected by
preparation/ transport conditions of the PT
specimens, matrix effects, clerical errors, selection
of statistical methods of evaluation, and peer group
definition. It is not appropriate to use PT as the only
means for evaluating the quality of a laboratory
as it will not detect all problems in the laboratory,
particularly those that address the pre and post
analytical processes. In conclusion PT programs
can be an efficient tool in assessing a laboratory’s
analytical systems/methods. However complete
utility of any PT program requires complete
understanding of the PT report issued.

Sources of Pre-analytical Variations
Dr Khushbakht Arbab
Chemical Pathology

Laboratory testing can be divided into three phases
that is pre-analytical phase which begins with
the patient and ends with preparation of a sample
for testing, analytical phase which includes steps
involved in the actual performance of a laboratory
test and post analytical phase which begins with the
4

reporting of results to the health care provider and
ends with actions being taken by the health care
provider that are based on test results. A common
assumption is that errors are most likely to occur in
the analytical phase, the component of laboratory
testing considered the most complex. Perhaps
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as a consequence of the focus on technological
improvements, it is actually the pre-analytical phase
in which most errors occur. The healthcare providers,
laboratory staff and the patients themselves should
be aware of the common causes of pre-analytical
errors. These errors can be further divided into
pre-collection, blood collection and post collection
causes (Table 1). To prevent pre-analytical errors, the
procedures for collection, handling, and processing
prior to analysis, as well as the physiologic patient
variables that may directly affect the test result, must
be clearly understood.
Specimen composition is influenced by any of
the patient variables listed in Table 1. Some
are controllable, some are not. The laboratory
personnel must be aware of these influences and
minimize the effects when possible. For example,
in the basal state, a patient is at rest and fasting.
Collection of a blood specimen from a patient in
that state minimizes the effect of diet, exercise,
and other controllable factors. A broad category
of variables related to phlebotomy technique and
procedures can introduce pre-analytic error. A
few studies have demonstrated that pre-analytical
errors are less common when dedicated laboratory

personnel collect blood samples as opposed to
nursing or other health care personnel. Unacceptable
specimens due to misidentification, insufficient
volume to perform the assay, incorrect whole
blood to anticoagulant ratio, or specimen quality
issues (specimens that are hemolyzed, clotted,
contaminated, or collected in the wrong container)
account for the majority of pre-analytic errors.
Hemolysis, lipemia, and icterus have variable effects
on assays. How a specimen is handled from patient
to laboratory is another area of potential error and
mostly outside control of the testing laboratory.
Careful handling of the specimen during transport
and processing is imperative in maintaining the
quality of a meticulously collected specimen. The
means of transport, exposure to heat and cold,
vibration, position of specimen tubes and overall
time to delivery can significantly affect test results.
The pre-analytical phase is complex and with
so many people involved in the blood collection
process, it is not surprising that errors can
occur. However, good practices, teamwork, and
compliance with the established procedures and
instructions can lead to a substantial reduction in
pre-analytical errors.

Table 1: Preanalytical Causes of Errors Divided into Pre-collection, Blood collection and Post collection Phases

Pre-collection Phase Variables


Wrong/ inappropriate test request

Test

request written illegible

Patient

contributions:

Blood Collection Phase Variables

Post Collection Phase Variables

Posture

Exposure

to sunlight

Time

Exposure

to inappropriate temperature

of collection

Faulty

phlebotomy technique

Diurnal

consideration

Tourniquet

Fasting

requirement for certain tests

Skin

time (not >1 minute)

preparation

Delay

in transport

Hemolysis
Breakage

or leakage

Exercise

Hemolysis

Delay

Stress

Clots

Evaporation

Age

Under

filling of tubes

Faulty

 Medications

Cross

contamination between tubes

Poor

Smoking

Skin

Dehydration

Inadequate

Wrong

labeling/ wrong barcode

in sample

contamination

Quantity

mixing

centrifugation

specimen storage condition

Incorrect
Wrong

aliquots

labeling

not sufficient for analysis

Wrong

vacutainer tube

Wrong

order of draw

Air

in processing

introduced in the sample

Venous

sampling when arterial blood

is required or venous mixing
Presence

of intravenous fluids on the

arm

5
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Critical Values in Surgical Pathology
Dr Nausheen Azam and Dr Arsalan Ahmed
Histopathology

Occasional diagnoses in surgical pathology,
analogous to critical values (CVs) in clinical
pathology, could require urgent contact of the
clinician to facilitate rapid intervention. However,
there are no established guidelines as to what type
of diagnosis in surgical pathology should qualify as
a critical value (CV).
The concept of critical value (CV) was
first introduced by Lundberg in 1972 as a
“pathophysiologic derangement at such variance
with normal as to be life threatening if therapy
is not instituted immediately.” Since the
introduction of the CV concept, the practice
of notifying clinicians of CVs has become the
standard of practice in clinical pathology, with
well established guidelines for which specific
laboratory results require that the laboratory
personnel immediately contact the clinician

responsible for the patient. The Clinical
Laboratory Improvement Amendments of 1988,
states that “the laboratory must develop and follow
written procedures for reporting life threatening
laboratory results or panic values.” The College
of American Pathologists (CAP) checklist also
includes a requirement asking if there is a policy/
procedure regarding the timely communication and
documentation of “significant” or “unexpected”
surgical pathology findings.
However there are no well defined guidelines
to address the concept of CVs in surgical
pathology. Therefore in the absence of
established guidelines and since surgical
pathology results are not measured in numbers,
common sense and personal experience of the
pathologist determines when to urgently contact
the clinician.

Table 1: Examples of Critical Diagnoss in Anatomic Pathology

Cases that have immediate clinical consequences
Crescents in > 50% of glomeruli in a kidney biopsy
Leukocytoclastic vasculitis
Uterine contents without villi or trophoblast
Fat in an endometrial curettage
Mesothelial cells in a heart biopsy
Fat in colonic endoscopic ploypectomies
Transplant rejection
Maligancy in superior vena cava syndrome
Neoplasms causing paralysis
Unexpected or discrepant findings
Significant disagreement between frozen section and final diagnosis
Significant disagreement between immediate intepretation and final FNA diagnosis
Unexpected malignancy
Significant disagreement and/or change between primary pathologist and outside pathologist consultation (at
either the orginal or consulting institution)
Infections
Bacteria or fungi in cerebrospinal fluid cytology in immunocompromised or immunocompetent patients
Pneumocystis, fungi, or viral cytopathic changes in bronchoalveolar lavage,bronchial washing or brushing
cytology specimens in immuncompromised or immunocompetent patients
Fungi in FNA of immuncompromised patients
Bacteria in heart valve or bone marrow
Herpes in Papanicolaou tests of near-term pregant patients
Any invasive organism in surgical pathology specimens of immuncompromised patients
Abbreviation: FNA, Fine needle aspiration

6
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The Association of Directors of Anatomic and
Surgical Pathology (ADASP) has supported the
concept of critical diagnoses (CVs) in surgical
pathology, recognizing that critical diagnosis
guidelines would be of great help to surgical
pathologists and, ultimately, facilitate the clinicians.
As a result, several retrospective reviews and multiinstitutional surveys led to the creation of a list of
possible critical diagnoses in surgical pathology and
cytology (Table 1).
ADASP recognizes that a generic anatomic
pathology critical diagnosis guideline such as the one
mentioned above should be used only as a template
and it should be left to the individual hospital to
customize the list following consultation with their
relevant clinical services. While establishing the CVs

VOL. 41, ISSUE 1

guidelines it is also important to avoid overuse and
remove non-critical diagnosis type cases from the
list.
In conclusion, it is important to establish a
surgical pathology CV guideline, because there
are some diagnoses in surgical pathology which
are life threatening and require fast remedial
action for improved patient outcome, and
secondly the presence of these guidelines would
represent a practice improvement and patient
safety initiative.
References:
Lundberg GD. When to panic over an abnormal value. MLO Med Lab
Obs 1972;4:47-54
Critical diagnoses (critical values) in anatomic pathology. Human
Pathology (2006)37, 982-984

Five Q-Framework for Implementing Total
Quality Management in Laboratory
Dr Noreen Sherazi
Chemical Pathology

There has been a continuous challenge in the health
care system to provide better diagnosis, while
maintaining standard quality credentials. Total
Quality Management (TQM) include all divisions
of the organization, namely, laboratory operations,
information management, documents and record
maintenance, materials and purchase, customer
care, safety etc. Quality Management System
requirements cover management’s commitment to
quality, its focus on customer, resource management,
employee competence, process management,
quality planning, design, purchasing, monitoring
and measurement of its processes, calibration of
measuring equipment, processes to resolve customer
complaints, corrective/preventive actions and
continuous quality improvement program.
The traditional framework for quality management in
a healthcare laboratory emphasizes the establishment
of following processes i.e. (Figure 1)
(1) Quality Laboratory Processes (QLPs)
(2) Quality Control (QC)
(3) Quality Assessment (QA)
(4) Quality Planning (QP) and
(5) Quality Improvement (QI)
QLPs include analytical processes and the general

Figure 1: TQM Framework for Managing Quality in Healthcare Laboratory

policies, practices, and procedures that define how
all aspects of the work are done. QC emphasizes
statistical control procedures, but also includes
non-statistical check procedures, such as linearity
checks, reagent and standard checks, and temperature
7
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monitors. QA, as currently applied, is concerned
primarily with broader measures and monitors of
laboratory performance, such as turnaround time,
specimen identification, patient identification and
test utility. Note that QA is the proper term for these
activities, as opposed to quality assurance, which
has been incorrectly used to describe these activities.
Measuring performance does not by itself improve
performance and often does not detect problems in
time to prevent harmful effects. QA requires either
that causes of problems be identified through Ql and
eliminated through quality planning (QP) or that QC
detect the problems early enough to prevent their
consequences.
To provide a fully developed framework for quality
management, the QI and QP components must
be established. QI provides a structured problemsolving process to help identify the root cause
of a problem and a remedy for that problem. QP
is necessary to standardize the remedy, establish
measures for performance monitoring, ensure that the
performance achieved satisfies quality requirements
and document the new QLP. The new process then is
implemented through QLP, measured and monitored
through QC and QA, improved through QI, and
replanned through QP. The “five-Q framework” also
defines how quality is managed objectively with
the “scientific method,’’ or the PDCA cycle (plan,
do, check, act). QP provides the planning step, QLP
establishes standard processes for the way things
are done, QC and QA provide measures for checks

Table 1: Essentials of TQM
Organization
Customer Focus
Facilities and Safety
Personnel
Purchasing and Inventory
Equipment
Process Management
Documents and Records
Information Management
Nonconforming Event Management
Assessments
Continual Improvement
Reference: CLSI guidelines QMS: A Model for Laboratory Services
GP26-A4

on how well things are done, and QI provides a
mechanism through which, to act on those measures.
Clinical and Laboratory Standards Institute (CLSI)
document describes a quality management system
(QMS) as a “set of key quality elements that must
be in place for an organization’s work operations
to function in a manner to meet the organization’s
stated quality objectives.” These Quality System
Essentials (QMEs) are listed in Table 1. These depict
the necessary infrastructure required by a laboratory
to provide quality laboratory services which is
implemented and monitored by five Q-framework to
achieve the quality goals.

Delta Check in Clinical Laboratory
Hafsa Majid
Chemical Pathology

Decisions about diagnosis, prognosis and treatment
are based on the results and interpretations of
laboratory tests, and irreversible harm may be caused
by erroneous test results. So early error identification
have considerable implications for patient care
and safety. Delta check is a very useful quality
improvement measures that can help the laboratory
identify possible patient-specific errors. It is a quality
control method that compares the current test result
with a previous result for the same test obtained over
a short period of time (preferably within 96 hours)
from the same patient and detects whether two values
8

exceeds predetermined biological limits. A delta
check failure or alert is caused by a discrepancy in
patient results. It occurs when the difference between
the patient’s current laboratory result and previous
result exceeds a pre-defined limit with a pre-defined
length of time.
Delta check methods ensure the detection of preanalytical errors (e.g. specimen mix-up errors,
improper specimen acquisition, specimens altered by
dilution with intravenous fluid, EDTA contamination,
possible misidentification of a specimen and
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transport error), clerical errors, biological variation
(e.g. changes due to due to rhythmic, physiological
or therapeutic changes) and random errors (e.g.
sudden instrument or method related errors). If no
error is identified in total testing process differences
in results is due to a true change in patient’s disease
status. These errors cannot be detected using
commonly used quality control methods; thereby
delta check improves the reliability of clinical tests.
There are four delta check methods: delta difference,
delta percent change, rate difference, and rate percent
change. However, guidelines regarding decision
criteria for selecting delta check methods have not
yet been provided. Delta check methods statistically
can be defined as:





Delta Difference = Current Result – Previous Result
Delta Percentage Change = Current- Previous Result X 100%
Previous Result
Rate Difference = Delta Difference / Delta Time
Rate Percentage Change= Delta Percentage Change/Delta Time

Studies have found that the majority of delta check
failures (>75 per cent) can be attributed to true
changes in the patient’s medical condition and

predictive value for detecting true specimen errors
is between 0.4 and six per cent. Some analytes are
more useful for delta checks than others. Ideally,
analytes for delta checks should have little day-today variation, low reference change value and low
index of individuality. Some common analytes on
which delta check can be applied are listed in Table 1.
Table 1: Biochemical Analytes for Delta check Application
Appropriate analytes

Inappropriate analytes

Electrolyte ( Na+, K+ & Cl-)

Glucose

Albumin

Phosphorus

Total Protein

Aspartate transaminase

Urea

Alanine transaminase

Creatinine

Creatinine Phosphokinase

Alkaline Phosphatase

Lactate Dehydrogenase

Modern automated analyzers now have the option
of delta check flags in them. However to make this
function practically possible delta check limits have
to be derived for each analyte. In conclusion the
delta check based quality control is very useful in
identifying errors missed by laboratory quality control
procedures and these programs should be performed
in parallel with routine quality control practices.

Indicators of Quality Improvement in
Surgical Pathology
Dr Muhammad Usman Tariq and Dr Arsalan Ahmed
Histopathology

A quality assurance program is meant to identify
problems and recognize opportunities for
improvement. The first step is the development of
quality indicators which cover the most important
aspects of patient care. Only few quality indicators
have been identified by the surgical pathology
laboratories worldwide. Few important variables of
analytic and postanalytic phase are described in this
article.
Diagnostic Accuracy (Intradepartmental Peer
Review)

identification of quality issues. Retrospective
peer review often targets diagnostic biopsies
with increased potential for adverse outcomes,
recent cancer diagnoses, specific specimen types
with known diagnostic difficulties and frequent
mimics. The common examples include daily slide
conference and reviews requested by the clinician
in case of report ambiguity and lack of correlation
with clinical findings. Other activities such as tumor
boards, audits of cases sent to outside institution
for routine review and audits focused on specific
specimen types.

Quality in surgical pathology depends on the
correctness of report which is assured by peer
review which provides the opportunity to collect
comprehensive information and straightforward

The responsibility remains with the primary signout pathologist who issues a revised/amended
report if the diagnosis is after the review is
changed.
9

VOL. 41, ISSUE 1

MARCH 2015

Diagnostic Accuracy
(Interinstitutional Peer Review):

Table 1: Monitors used to Assess Report Adequacy

Data Element

External review can be initiated
Specimen of any type
Patient identification
on the request of patient,
Pertinent clinical history
Specimen site
clinician or pathologist but most
Statement of specimen adequacy (when appropriate)
importantly on institutional
Adequate macroscopic description
request because of patient’s
Clear diagnostic terminology
transfer. Studies have shown
Primary
cancer
specimens
Tumor size
that these reviews revealed
Histologic type
discordance in diagnosis including
Histologic grade (if appropriate)
false –positive, false-negative,
Extent or depth of invasion (if appropriate)
Number of lymph nodes examined
change in tumor type/grade,
Number of nodes with metastasis (if any)
resection margin status and stage
Status of surgical margins (if appropriate)
change. In addition, application
Image-guided biopsies
A comment on specimen adequacy
of additional and/or repeat
A comment on whether the biopsy findings correlate
immunohistochemical stains
with the imaging findings (eg. whether the findings
results in significant change in
explain the targeted abnormality)
diagnosis. In future, molecular
The presence of calcification in a biopsy performed
for that reason
diagnostics is further going to
alter the diagnosis when reviewed
in different institutions. For institutions treating
Moreover, monitoring of the reports for missing
new patients, the Association of Directors of
information has now become easier.
Anatomic and Surgical Pathology (ADASP)
recommends mandatory review of biopsy of
Turnaround Time (TAT)
cases for which major therapeutic intervention is
planned.
TAT is as important as diagnostic accuracy and
adequacy of a report and therefore, it is a critical
Correlation of Intraoperative and Final Diagnosis
component of patient care because of its impact
(Frozen Sections)
on patient management. It is influenced by several
factors related to the working of a hospital,
It is an integral component of quality
anatomic pathology laboratory, with technical,
improvement and it should be conducted on all
clerical and human interpretive processes.
the cases submitted for frozen section. It requires
Turnaround time data can help to identify the
review of the slides prepared for frozen section
problems, their analysis and possible modification
and the slides prepared after formalin fixation.
of the process in order to improve the overall
Reasons for discordant results (in order of
service and eventually patient outcome.
decreasing frequency) include misinterpretation,
specimen sampling, block sampling,
Table 2. ADASP Benchmarks for Surgical Pathology Turnaround Times
technical inadequacy, inadequate clinical
data and labeling errors.
Type of Specimen
Report Finalization
Report Adequacy
Adequacy or completeness of the report
is extremely important in cancer cases
as the treatment relies on the complete
information. College of American
Pathologists and Royal College of
Pathologists have devised comprehensive
checklists and protocols for different
cancers. Laboratories all over the world
are adopting the synoptic reporting which
presents all the essential information (data
elements) required in an efficient manner.
10

Frozen sections
Rush biopsies
Biopsies (small)
Surgical specimens

20 minutes
2 days
3 days
3 days

Additional Time for Special Procedures
Overnight fixation
Decalcification
Regrosses
Recuts
Immunohistochemistry
Electron microscopy
Intradepartmental consultation

1 day
1 day
1-2 days
1 day
1-2 days
2-3 days
1 day

Reference: Quality Management in Anatomic Pathology. Chapter 6: Quality improvement
plan components and monitors. 2005 College of American Pathologists (CAP)
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Types of Analytical Errors
Shabnam Dildar
Chemical Pathology

Laboratory errors are normally classified into two
categories; random errors (RE) and systematic
errors (SE). Random errors are type of analytical
error which arises from random fluctuations in
measurement (Figure 1). Systematic error is defined
as a component of error which, in the course of a
number of analyses of the same analyte, remains
constant or varies in a predictable way (Figure 2).
Total analytical error =SE + RE. Statistically total
error is defined as Bias + 1.65 x Imprecision. Under
ideal circumstances, total analytical error equals to
zero, but this cannot be achieved in daily practice.

Random error affect the precision of all measurements,
higher the precision of a measurement instrument,
the smaller the variability (standard deviation) of the
fluctuations in its readings. Large RE increases the
dispersion of the results around a true value.
Systematic Error: Systematic errors can be
attributed to certain reasons and therefore can
be eliminated much easier than RE. They cannot
be diminished by increasing the number of
measurements. Some common causes of SE are:

Incorrectly made standards, controls or reagents

Instrumentation defects

Variation in pipettes and volumetric glassware

Variation in cuvettes

Electronic and optical variation in instruments
Systematic errors are subdivided into the following
two types:

Figure 1: Representation of the values’ dispersion in RE

Constant systematic error: When the error is
consistently low or high by the same amount,
regardless of concentration it is called constant
systematic error. Factors that contribute to constant
systematic error are independent of analyte
concentration.
Proportional systematic error: When the error is
consistently low or high by an amount proportional
to the concentration of analyte is called proportional
systematic error.

Figure 2: Representation of the values’ dispersion in SE

Table 1 presents an organization of experiments to be
performed for specific error determination arranged
in such a way that easy experiments can be done first
and final performed only if errors estimated by these
preliminary experiments are acceptable.

Random Errors: cannot be absolutely identified
(can occur due to differences in
Table 1: Experiments for Estimating Specific Types of Analytical Errors.
techniques between technologists,
specimen characteristics, etc.) Some
Evaluation Experiments
Type of Analytic
common causes of RE are:
Preliminary Study
Final Study
Error

Instability of instrument
RE
Replication With In Run (using Replication run to run

Variation in the temperature
pure material, patient specimens) (using patient specimens)

Variation in reagents and calibrators
Constant Error
Interference
Comparison with
(poor calibration curve stability)
comparative method

Variation in handling techniques such
Proportional
Error
Recovery
Comparison with
as pipetting, mixing, and timing
comparative method

Variability in operators

11
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Validation of Modern Flow Cytometry Instrument
Dr Muhammad Shariq Shaikh, Dr. Arsalan Ahmed and
Sarwat Kashif
Haematology and Histopathology

Flow cytometry is a dynamic technology
which allows the multi-parameter evaluation of
heterogeneous cell populations. Over the years,
clinical flow cytometry has evolved as a distinct
haematopathology diagnostic facility. Considering
the requirement put forth by regulatory agencies
and the complexity of multi-parameter analysis by
flow cytometry, standardization and validation of
flow cytometry instrument, reagents and procedures
are essential to ensure interpretation of meaningful
technical results. In this article, validation of flow
cytometry instrument will be the primary focus.
Validation of flow cytometry instrument includes
instrument setup, daily calibration of both light
scatter and fluorescence measurements and crossinstrument performance using relevant clinical
specimens.
Instrument Setup
Manufacturer recommended procedures must
strictly be followed to assure proper optical
alignment for adequate light scattering,
fluorescence sensitivity and resolution. Additionally
when multiple fluorochromes are used, fluorescence
compensation is essential to correct for spectral
overlap.
Calibration of Light Scatter and Fluorescence
Measurements
Optical alignment for optimal sensitivity and
resolution of both forward (FSc) and side (SSc)
scatter can be assessed by running uniformly
sized beads that fall within the light scatter ranges
observed with most clinical samples on a daily
basis. The mean FSc and SSc channel numbers
and percent coefficient of variation (CV) should
be recorded. The acceptable ranges for each
parameter can be established by running the beads
20 times over a five day period at the same photo
multiplier tubes (PMT) setting. Levy–Jennings
graphs are then used for validation by plotting
the values obtained daily and an action plan is
established for what to do when any parameter
falls outside of the expected range. Owing to the
12

difference in behavior of cells and beads, setting
up of instrument using biological material (for
example lymphocytes) is also recommended
before running clinical samples. Similarly for
establishing values for monitoring fluorescence
sensitivity and resolution, recording of either the
channel number and C.V of calibration beads or
alternatively, the high voltage and gain to position
the beads in the same channel each time.
Utilization of multiple fluorochromes is associated
with spill-over of one fluorescence signal into
another. For this, fluorescence compensation using
a combination of biological control and hard dyed
beads provided by manufacturer is preferable. For
fluorescence linearity, a mixture of 4-5 known multilevel fluorescence beads should be run 20 times over
a five days period to establish mean fluorescence
intensity (MFI) ranges. Monthly fluorescence
linearity should be stable unless the laser or PMT is
unstable.
Cross-Instrument Performance
It should be done by laboratories performing the
same clinical immunophenotyping protocols on more
than one instrument. Five different representative
clinical samples must be tested every six months.
Corrective actions must be taken when crosscomparison results fail to meet performance
specifications.
In conclusion, validation of instruments, reagents
and procedures is the responsibility of diagnostic
facility to ensure good laboratory practice and is
integral to provide good patient care.
At Aga Khan University clinical laboratories,
immunophenotyping by flow cytometry is offered
for the diagnosis of leukaemia, lymphoma, minimal
residual disease, ZAP-70 expression, lymphocyte
subsets and CD34 count.
Reference:
Owens MA, Vall HG, Hurley AA, Wormsley SB. Validation and quality
control of immunophenotyping in clinical flow cytometry. J Immunol
Methods. 2000 21;243(1-2):33-50.
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Method Validation for Quantitative Tests:
CAP Recommendations
Dr Noreen Sherazi
Chemical Pathology

According to Food and Drug Administration,
validation is ‘‘Establishing documented evidence
which provides a high degree of assurance that a
specific process will consistently produce a product
meeting its predetermined specifications and quality
attributes.” College of American Pathologist (CAP)
regulations require that performance for any new
method be ‘‘verified’’ prior to reporting patient’s
test results. Precision and accuracy are specifically
identified, along with analytical sensitivity, analytical
specificity, reportable range, reference values, and
any other applicable characteristic. The responsibility
for method verification or validation resides with
each laboratory and is accountable to see that
adequate data has been collected and that this data
shows that the new methods provide acceptable
performance in the laboratory. Following protocol
should be followed in validating a new test and it
should be documented.
Verification of Precision
Precision implies repeatability, which means,
analyze repeatedly to determine variation. To verify
precision, samples should be processed twice a
day in quadruplicate for five days generating 20
replicates. This is called inter-assay variation. For
intra-assay variation, one sample was run 20 times.
Imprecision is quantified by calculating the mean,
standard deviation (SD), and coefficient of variation
(CV %) of data collected from an analytical run: CV
= SD/Mean x 100.Precision can be specified as: (i)
repeatability (within run), (ii) intermediate precision
(long term) and reproducibility (interlaboratory). If
the precision is less than the total allowable error for
that analyte then method is precise.
Verification of Accuracy
Agreement between test result and ‘‘true’’ result is
done in mainly two ways:
(i) Comparison of results between new method and
‘‘reference’’ method (Method comparison)
(ii) Results using new method on certified reference
materials or controls (Recovery)

The first approach is most commonly used. For this
run 20 samples within testing range (CLSI document
EP15-A2) by both new and comparative methods,
and check whether the average bias between the two
methods is within allowable limits or not. Recovery
is done when there is no comparative method
available and it should also be within total allowable
error for the accuracy to be verified.
Verification of Reportable Range (AMR & CRR)
Reportable range is the span of test result values over
which the lab can establish or verify the accuracy of
the measurement response.
Analytical Measurement Range (AMR)
Range of analyte values that a method can directly
measure on the specimen, without any dilution,
or other pretreatment, not part of the usual assay
process. AMR must be verified before a method is
introduced, and checked at least every six months
(and after recalibration or major maintenance) while
in use. AMR verification must include three levels—
low, midpoint, high. One can use commercial
linearity materials, proficiency testing (PT) samples,
controls or patient samples with known results,
standards or calibrators. It can also be done by
calibration verification, if three samples that span
the measurement range are used. In absence of
commercial materials, one will need to create one’s
own materials. High and low samples can be mixed
to create a mid-point sample. If it is found to be
higher than measurement limit, one can dilute with
low level sample to create a level near limit.
Clinically Reportable Range (CRR)
It is the range of analyte values that are reported as
a quantitative result, allowing for specimen dilution
or other pretreatment used to extend the actual AMR.
CRR is a clinical decision by the laboratory director/
section heads, and does not require experiments or
re-validation; however, dilution or concentration
protocols must be specified in methods.
13
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Verification or Establishment of Reference
Intervals
It is not required for a laboratory to establish its
own reference limits, but satisfy that limits it uses
are appropriate for the patients. According to CLSI
document C 28-A2, it is very useful to be able to
transfer a reference interval from one laboratory
to another by some process of validation which is
less costly and more convenient. One can adopt
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reference limits from any of the following sources:
manufacturer suggested, reference laboratory,
published articles, neighboring laboratory or
previous reference limits in the same laboratory.
For verifying reference intervals, we should select
20 representative healthy individuals, and the test
will considered validated if, ≤ 2 of them is outside
the manufacturer’s proposed limit. If >2 outside,
can repeat with another 20, and accept if ≤ 2 is
outside.

Barcoding for Reducing Pre-analytical Errors
in a Clinical Laboratory
Sheharbano Imran
Chemical Pathology

Barcode is a system of using varying width bars
as a way to provide identification information. It
is an optical machine-readable representation of
data, which shows certain data on certain products.
in laboratory. Its purpose is to ensure sample
identification and accession. Bar codes consist of
a series of small parallel lines of varying width
that are used to represent numbers or letters and
numbers and are readable by automated equipment.
There are many types of barcodes the most common
ones being one dimensional and two dimensional.
In single dimensional barcode the vertical lines
and their spacing constitute the code but whole
length of the vertical lines are not essential for the
codes. It is said that the code is repeated in vertical
directions. So a symbol with printing defects, such
as spots or voids, can still be read. On the other
hand, two dimensional barcode stores information
along the height as well as the length of symbol.
As a result of that construction, these barcodes
have a greater storage than is possible with the one
dimensional barcode. A two dimensional barcode
is not comprised of bars or lines, but rather of
black-and-white cells arranged in a matrix pattern
(often laid out in a square). This square design is
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often easier to scan than lineal barcodes because it
fits better on curved surfaces such as test tubes or
patient wristbands.
Bar-coding the specimen label greatly
minimizes clerical errors and decreases errors
in patient specimen handling as well as increase
productivity. For clinical laboratories, timely and
accurate specimen labeling is expected to ensure
correct patient identification from collection to
results reporting. Electronic identification such as
two dimensional barcodes can certainly include
two or more person-specific identifiers to comply
with this requirement. Barcodes clearly provide
patient tracking and sample management. They
speed up record retrieval and are more secure
for patients in terms of anonymity, accuracy,
and elimination of human error. With barcodes,
transcription errors and hard-to-read labels can be
removed from the workplace. Besides laboratory
specimens barcodes can be used on reagents/ kits,
quality controls, calibrators and blood products in
a clinical laboratory. With a high quality barcode
label, a working scanner, and a trained operator,
data collection can happen at lightening speeds
with 100 per cent data accuracy.

MARCH 2015

VOL. 41, ISSUE 1

Levey Jenning Chart and a Guide to Use
Westgard Rules
Dr Sheharbano and Dr Lena Jafri
Chemical Pathology

Levey Jenning chart (LJ chart) is a graph on
which the quality control data is plotted on. It is
named after S. Levey and E. R. Jennings who in
1950 suggested the use of Shewhart’s individuals
control chart in the clinical laboratory. It is a
visual indication whether a laboratory test is
working well or not. The data obtained from the
daily analysis of quality control pools can be
plotted to create a visual analysis. The expected
analyte concentration, the established target
value (mean), and the desired number of standard
deviations are drawn on the y-axis, and the days of
the month are indicated on x-axis. Lines run across
the graph at the mean, as well as one, two and
sometimes three standard deviations either side of
the mean. This makes it easy to see how far off the
result was.
Rules, such as the Westgard rules can be applied
to see whether the results from the samples
when the control was done can be released, or
if they need to be rerun. In 1981, Dr. James
Westgard and his associates developed a multirule procedure for interpreting control data. Since
then, a number of sophisticated quality control
schemes or analogues based on this multi-rule
logic have evolved. Westgard rules are quality
control rules to help analyze whether or not an
analytical run is in-control or out-of-control. Any
values violating Westgard rules will be either
rerun or rejected depending on the rule violated.
It uses a combination of decision criteria,
usually five different control rules to judge the
acceptability of an analytical run. Westgard rules
specify the LJ chart. It makes use of a series of
control rules for interpreting control data and
also reduces the false rejection and improves
the error detection. The formulation of Westgard
rules were based on statistical methods. They are
used to define specific performance limits for a
particular assay and can be used to detect both
random and systematic errors. For convenience,
a short hand notation to abbreviate different
decision criteria or control rules, e.g., 12s to
indicate one control measurement exceeding 2s
control limits is used.

Explanation of Individual Rules and
Troubleshooting
12s : One control measurement exceeding two
standard deviations (SD) of control limits either
above or below the mean. This rule is used a warning
rule to trigger careful inspection of the control data.
(Figure 1) False alarms are minimized by using
the 12s rule as a warning rule, then confirming any
problems by application of more specific rules that
have a low probability of false rejection.
13s : This rule is commonly used with a LJ chart
when the control limits are set as the mean +3 SD
of control limits. A run is rejected when a single
control measurement exceeds the mean ± 3 SD.
This is because either a random error or a very large
systematic error has occurred, as less than one per cent
of all test values exceed ± 3SD. Troubleshooting must
be performed before further testing can be done.
22s : Westgard rule 22s states that if two
consecutive control measurements across runs
exceed the same mean -2 SD or exceed the same
mean +2SD, or, within a run, if two consecutive
control values are outside the same two SD, the
run must be rejected. If this circumstance occurs, a
systematic error is likely. Troubleshooting must be
performed before testing can continue. Had only
one of the controls been greater than +2SD, the
run would have been accepted as “in control,” but
would have been rejected on the next QC run if the
same control was again out +2SD.
R4s : This rule rejects a run if two control
measurements in a group exceed the mean with a four
SD difference between the two consecutive controls.
41s : This rule rejects a run with the forth consecutive
control measurement exceeding one SD on the same
side of the mean. 41s is when four consecutive control
measurements exceed the same mean plus one SD or
the same mean minus one SD control limit.
10x : This rule rejects a control run when there are 10
consecutive controls on the same side of the mean.
15
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Figure 1: Graphs showing interpretation of Westgard rules on LJ charts (courtesy westgard.com)

True alarms or error detection are maximized
by selecting a combination of the Westgard
rules most sensitive to detection of random
and systematic errors and then rejecting a run
if any one of these rules is violated (parallel
testing). The key in how to apply control rules
with multiple materials and multiple runs is to
identify which quality control results represent
consecutive measurements. For example if one
measurement is made on each of two different
control materials in an analytical run, control
rules can be applied as follows: the two control
results ‘within a run’ can be inspected by applying
16

a 13s rule to each material, as well as the 22s
and R4s rules ‘across materials’. Likewise
the 10x rule can be applied to both control
measurement in a run for the last five runs, or
to the measurements on just one material for the
last ten runs. Westgard rules are programmed
in to automated analyzers to determine when an
analytical run should be rejected. These rules
need to be applied carefully so that true errors
are detected while false rejections are minimized.
The rules applied to high volume chemistry and
hematology instruments should produce low false
rejection rates.
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Quality Control of VITEK-2 System
Asima S. Sabzwari
Clinical Microbiology

VITEK-2 system is an automated system for
antimicrobial susceptibility testing. As with any
automated system, it is very important to maintain
quality control (QC) as microbial contaminants can
enter a bio-manufacturing product system and impact
the product outcome. QC is also performed to check
that the instrument is functioning properly and all the
values are within the reference ranges.
Principle
VITEK-2 system use advanced colorimetry, an
identification technology that enables identification
of routine clinical isolates. Advanced colorimetry
provides a low rate of misidentified species and
susceptibility testing can be performed accurately in
a shorter period of time. The VITEK-2 Antimicrobial
Susceptibility Test (AST) card is an automated
version of determining the minimum inhibitory
concentration (MIC). Each AST card contains 64
wells including a control well and wells containing
premeasured portions of a specific antibiotic tested
against a standardized suspension of bacterial or
yeast isolates for 7-12 hours.
At the completion of the incubation cycle, a report
is generated that contains the MIC value along with
the interpretive category result for each antibiotic
contained on the card.
The rapid results allow clinicians to discontinue
empiric therapy and prescribe targeted therapy,

resulting in improved patient outcomes and enhanced
antibiotic stewardship.
Quality Control
The consistency of results as analysed by the Vitek
expert system indicates that the isolate fits an
expected pattern for a defined phenotype. Results can
be rapidly and confidently released with little or no
intervention by laboratory personnel. Daily protocols
are followed to control environmental factors and to
maintain sterility for assuring quality through day
to day operations. Important steps taken to maintain
quality control of the VITEK-2 System include:


QC of reference strains being done and the values
are compared with standards. The results must
be within recommended ranges as per guidelines
for susceptibility results to be valid.



VITEK-2 dispenser is cleaned with distilled water
to remove any deposits and autoclaved weekly to
maintain sterility.



The tips used are also autoclaved before preparing
suspensions



The tubes used for making suspensions are
sterilized by ethylene oxide



Sterility check is performed daily to rule out
the contamination of the dispenser and
Vitek saline to ensure that the saline and
dispenser are not contaminated with any
foreign particle/bacteria


VITEK-2 System

For each isolate to be tested, purity
plate is setup to ensure that the
isolate is pure at the completion of
the process. If the purity plates are
not pure then the results are not valid
and should be repeated.

Annual service conducted by
manufacturer and on monthly basis PPM
(planned preventive maintenance) by the
vendor.
17

MARCH 2015

VOL. 41, ISSUE 1

Proficiency Testing as a Quality Improvement
Tool in Clinical Microbiology Laboratories
Dr Kauser Jabeen
Clinical Microbiology

Infectious diseases are a great threat globally to
human health. The morbidity and mortality related
to infections is aggravated further in settings with
limited resources, lack of government commitment
and poor infrastructure. Clinical microbiology
laboratories are pivotal for the diagnosis of
infection and detection of antimicrobial resistance.
It is therefore extremely critical that laboratories
should ensure generation of accurate and precise
results. In order to produce quality assured
results it is essential that laboratories should have
quality management systems in place. Proficiency
testing (PT) is an external quality assessment
tool that is used to assess laboratory performance
and quality of results. It is recommended that
clinical laboratories should participate in the PT
programs. Alternate assessment of a split sample
approach should be followed for a test for which
an approved PT program is not available. The
laboratory could also perform blinded testing
of simulated specimens or use photographs or
photomicrographs for this purpose.
The components and requirement of PT include
enrollment in approved PT program, regular
participation, meet criteria set by the PT
program. It is essentially important that the PT
samples are processed using similar protocols
and methodology as a regular patient specimen
is tested. Repeat testing should be avoided and
all technologists involved in reporting should be
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provided with an equal opportunity to process
and report PT sample. The PT result should be
reported within the recommended time frame.
After receiving the result the results should be
compared with inter-laboratory comparison. In
case of an incorrect result, the process should be
reviewed to identify the cause of error. Corrective
actions should be taken and ongoing monitoring
continued.
Participation in a PT program could also be
helpful as it could be used as a bench mark quality
indicator of a laboratory. It could also be used as a
marketing tool to instill confidence in the customer
that this laboratory produces quality results. It
could be used a toll to assess staff’s competency
and as an education tool for teaching and training
of staff and junior doctors.
In conclusion regular participation in PT testing
program is essential for a clinical laboratory as it
is a valuable quality improvement tool. In Pakistan
this participation is not a regulatory requirement,
however many quality assured laboratories, such
as the Aga Khan University laboratory regularly
participate in the College of American Pathologists
PT program.
Reference:
Stang LH, Anderson NL. Use of proficiency testing as a tool to improve
quality in microbiology laboratories. Clin Microbiol Newletter 2013; 35:
145-52.
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Establishing Quality Control Values for
Haematology Parameters
Dr Muhammad Shariq Shaikh
Haematology

Quality control (QC) in the medical laboratory is
a statistical process used to monitor and evaluate
the analytical process that produces patient results.
A quality control product is a patient-like material
ideally made from human body fluids and contains
one or more analyte in known concentration. In
order to assess the validity of results on patient
specimens, use of QC material is a requirement
put forth by regulatory agencies. It is essential
for laboratories to fulfill or surpass the regulatory
standards set by regulatory agencies.

Calculation of own target values is a rather
easy task. The new control should be analyzed
a minimum of 20 times across three to five
days. The average of these 20 values should be
within the range stated on manufacturer provided
assay sheet. A two standard deviation range
should be calculated from this new target value
for setting up the upper and lower limits. These
new values should then be incorporated into the
system and utilized throughout the dating of the
product.

For most haematology analyzers, the target QC
value and its limits for each analyte are provided by
the vendor. These values are calculated by repeated
testing of QC material and are provided in an assay
sheet with each new lot of controls. However,
owing to variation in different laboratories,
instrument calibration, maintenance, reagents and
operator technique, these values may not be the
exact target value in a given laboratory.

Mean corpuscular volume (MCV) is a
haematology parameter that requires special
consideration. It has tendency to rise by two
units over the life of the control material. To
accommodate this, it is acceptable to raise the new
calculated target value by half this change (by one
unit). This will result in values starting below the
mean, rise through the mean and finish above the
mean.

Both The Joint Commission on Accreditation
of Health Care Facilities (JCAHO) and College
of American Pathologists (CAP) recommend
calculation of own target values by each laboratory.
This approach may not be a cost-effective option
for the laboratories catering small number of patient
samples. Utilization of manufacturer provided
QC values however, is permitted as a guide for
establishing own QC values and for very low
volume tests where the range is narrow enough to
detect clinically significant errors.

One drawback of establishing own QC values is
an increased utilization of expensive commercial
controls. However, in view of recommendations of
regulatory bodies, each laboratory should establish
its own quality control values to ensure reliability
of test results thus avoiding medically significant
errors.
References:
The Joint Commission - www.jointcommission.org
College of American Pathologists - www.cap.org
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